Overview of methodologies and statistical strategies in observational studies and meta-analyses on the risk of hepatocellular carcinoma in patients with chronic hepatitis B on entecavir or tenofovir therapy

Abstract

Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are first-line antiviral therapies for patients with chronic hepatitis B (CHB) and reduce the risk of disease progression and liver-related complications, as well as improve survival by effectively suppressing viral replication. Nevertheless, since the first publication in 2019 on a lower risk of hepatocellular carcinoma (HCC) in Korean patients receiving TDF than those receiving ETV, the topic has remained a hot and unsettled debate. Multiple studies and meta-analyses have yielded conflicting results. As HCC takes time to develop, studies are mainly observational to benefit from a larger sample size and longer follow-up that provides a higher statistical power to compare the two treatments. However, TDF was available to CHB patients a few years later than ETV in most countries, thus leading to a difference in follow-up duration. Moreover, despite studying the same topic, the difference in data sources and available parameters, inclusion and exclusion criteria, and use of statistical methods complicated the interpretation and comparison of the findings and contributed to between-study heterogeneity in meta-analyses. This review describes some caveats in interpreting and comparing the results from these observational studies and meta-analyses. Future studies should explore better designed observational studies with high-quality data sources, and aggregation of patient data in meta-analysis to tackle between-study heterogeneity.

Keywords

Bias / confounding / hepatitis B virus / hepatocellular carcinoma / liver cancer / nucleos(t)ide analogues / propensity score

References

[1] Sarin SK,Lau GK.Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Hepatol Int2016;10:1-98 PMCID:PMC4722087

[2] Association for the Study of the Liver. Electronic address: [e-mail]., European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.J Hepatol2017;67:370-98

[3] Terrault NA,McMahon BJ.Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.Hepatology2018;67:1560-99 PMCID:PMC5975958

[4] Choi J,Lee J,Ko MJ.Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: A Korean Nationwide Cohort Study.JAMA Oncol2019;5:30-6 PMCID:PMC6439769

[5] Kim SU,Lee HA.A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.J Hepatol2019;71:456-64

[6] Yip TC,Chan HL,Lui GC.Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China.Gastroenterology2020;158:215-225.e6

[7] Tseng C,Chen T.Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol2020;5:1039-52

[8] Choi WM,Lim YS.Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis.Clin Gastroenterol Hepatol2021;19:246-258.e9

[9] Petri H.Channeling bias in the interpretation of drug effects.Stat Med1991;10:577-81

[10] Ankarfeldt MZ,Groenwold RH,Ali MS.Assessment of channeling bias among initiators of glucose-lowering drugs: a UK cohort study.Clin Epidemiol2017;9:19-30 PMCID:PMC5261549

[11] Papatheodoridis GV,Idilman R.Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.J Hepatol2020;73:1037-45

[12] Chen CH,Wang JH,Hung CH,Peng CY.Comparison of incidence of hepatocellular carcinoma between chronic hepatitis B patients with cirrhosis treated with entecavir or tenofovir in Taiwan - a retrospective study.Am J Cancer Res2020;10:3882-95 PMCID:PMC7716174

[13] Su F,Ioannou GN.No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.Gut2021;70:370-8

[14] S; ANRS/AFEF study group. Similar 5-year HCC occurrence in tenofovir- and entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort.Aliment Pharmacol Ther2021;53:616-29

[15] Chang TS,Chen WM.Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B.Sci Rep2021;11:1365 PMCID:PMC7809351

[16] Shim JH,Kim KM.Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis.J Hepatol2010;52:176-82

[17] Yip TC,Tse YK.On-treatment improvement of MELD score reduces death and hepatic events in patients with hepatitis B-related cirrhosis.Am J Gastroenterol2018;113:1629-38

[18] Yip TC,Wong VW.Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B.J Gastroenterol Hepatol2020;35:1610-8

[19] Kumada T,Yasuda S,Ito T.Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis.J Viral Hepat2021;28:508-16

[20] Fu EL,Zoccali C,van Diepen M.Merits and caveats of propensity scores to adjust for confounding.Nephrol Dial Transplant2019;34:1629-35

[21] McCaffrey DF,Morral AR.Propensity score estimation with boosted regression for evaluating causal effects in observational studies.Psychol Methods2004;9:403-25

[22] Westreich D,Funk MJ.Propensity score estimation: neural networks, support vector machines, decision trees (CART), and meta-classifiers as alternatives to logistic regression.J Clin Epidemiol2010;63:826-33 PMCID:PMC2907172

[23] Güzelbulut F,Can G.Comparison of the efficacy of entecavir and tenofovir in reducing hepatocellular carcinoma risk in chronic hepatitis B patients: a real-life study in turkey.Turk J Gastroenterol2021;32:412-21

[24] Austin PC.An introduction to propensity score methods for reducing the effects of confounding in observational studies.Multivariate Behav Res2011;46:399-424 PMCID:PMC3144483

[25] Benedetto U,Angelini GD.Statistical primer: propensity score matching and its alternatives.Eur J Cardiothorac Surg2018;53:1112-7

[26] Austin PC.Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.Stat Med2009;28:3083-107 PMCID:PMC3472075

[27] Cepeda MS,Farrar JT.Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders.Am J Epidemiol2003;158:280-7

[28] Elze MC,Baber U.Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies.J Am Coll Cardiol2017;69:345-57

[29] Lee KJ,Cornish RP.STRATOS initiativeFramework for the treatment and reporting of missing data in observational studies: The treatment and reporting of missing data in observational studies framework.J Clin Epidemiol2021;134:79-88 PMCID:PMC8168830

[30] Sterne JA,Carlin JB.Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls.BMJ2009;338:b2393 PMCID:PMC2714692

[31] Rezvan P, Lee KJ, Simpson JA. The rise of multiple imputation: a review of the reporting and implementation of the method in medical research.BMC Med Res Methodol2015;15:30 PMCID:PMC4396150

[32] Jakobsen JC,Wetterslev J.When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts.BMC Med Res Methodol2017;17:162 PMCID:PMC5717805

[33] Little RJ,Cohen ML.The prevention and treatment of missing data in clinical trials.N Engl J Med2012;367:1355-60 PMCID:PMC3771340

[34] Choi H.Entecavir versus tenofovir for the prevention of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients in Korea.J Korean Med Sci2021;36:e89 PMCID:PMC8042481

[35] Gooley TA,Crowley J.Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.Statist Med1999;18:695-706

[36] Latouche A,Beyersmann J,Fine JP.A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions.J Clin Epidemiol2013;66:648-53

[37] Austin PC.Practical recommendations for reporting Fine-Gray model analyses for competing risk data.Stat Med2017;36:4391-400 PMCID:PMC5698744

[38] Burke DL,Riley RD.Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ.Stat Med2017;36:855-75 PMCID:PMC5297998

[39] Choi WM,Lim YS,Kim WR.Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments.J Hepatol2022;76:186-94

[40] Smith CT,Marson AG.Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes.Stat Med2005;24:1307-19

[41] Kim BG,Lee SB.Mortality, liver transplantation and hepatic complications in patients with treatment-naïve chronic hepatitis B treated with entecavir vs tenofovir.J Viral Hepat2018;25:1565-75

[42] Hsu YC,Chen CH.Tenofovir versus entecavir for hepatocellular carcinoma prevention in an international consortium of chronic hepatitis B.Am J Gastroenterol2020;115:271-80

[43] Lee SW,Lee HL.Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.Gut2020;69:1301-8 PMCID:PMC7306978

[44] Ha I,Jang ES,Kim JW.Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis.J Gastroenterol Hepatol2020;35:1774-81

[45] Oh H,Jun DW.Long-Term Safety Of Entecavir And Tenofovir In Patients With Treatment-Naive Chronic Hepatitis B Virus (CHB) Infection (SAINT) StudyNo difference in incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection treated with entecavir vs tenofovir.Clin Gastroenterol Hepatol2020;18:2793-802.e6

[46] Hu TH,Tseng PL.Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan.Aliment Pharmacol Ther2020;52:1695-706

[47] Shin JW,Jung SW.Comparable incidence of hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir or tenofovir.Dig Dis Sci2021;66:1739-50

[48] Na JE,Lee JH.Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response.J Viral Hepat2021;28:1392-9

[49] Zhang Z,Yang J,Huang Y.The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis.BMC Cancer2019;19:511 PMCID:PMC6542001

[50] Li M,Wu S.Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis.Hepatol Int2020;14:105-14

[51] Wang X,Dang Z.Nucleos(t)ide analogues for reducing hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis.Gut Liver2020;14:232-47 PMCID:PMC7096226

[52] Gu L,Shen Z.Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis.J Gastroenterol Hepatol2020;35:1467-76

[53] Kamal F,Marella HK.739 entecavir vs. tenofovir in prevention of hepatocellular carcinoma in patients with chronic hepatitis B: systematic review and meta-analysis.Gastroenterology2020;158:S-1289

[54] Liu H,Hayden JC,Rahmani J.Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B: a systematic review and meta-analysis.Liver Cancer2020;9:468-76 PMCID:PMC7506291

[55] Teng YX,Xiang BD.Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis.Gut2020;69:1900-2

[56] Cheung KS,Liu SH.Entecavir vs tenofovir in hepatocellular carcinoma prevention in chronic hepatitis B infection: a systematic review and meta-analysis.Clin Transl Gastroenterol2020;11:e00236 PMCID:PMC7544163

[57] Kim T,Lee YS.Comparison of the occurrence of hepatocellular carcinoma in patients of chronic hepatitis B with entecavir and tenofovir: a meta-analysis of Korean data.Hepatology2020;72:479A

[58] Dave S,Murad MH.Comparative effectiveness of entecavir versus tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B: a systematic review and meta-analysis.Hepatology2021;73:68-78 PMCID:PMC8022893

[59] Yuan J,Hao FB,Wang CR.No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis.Aging (Albany NY)2021;13:7147-65 PMCID:PMC7993671

[60] Jeong S,Park SM.Differential effectiveness of tenofovir and entecavir for prophylaxis of hepatocellular carcinoma in chronic hepatitis B patients depending on coexisting cirrhosis and prior exposure to antiviral therapy: a systematic review and meta-analysis.J Clin Gastroenterol2021;55:e77-86